End-Organ protection in patients with hypertension: Focus on the role of angiotensin receptor blockers on renal function

Drugs

Volumn 71, Issue 8, 2011, Pages 1003-1017

  Tocci, Giuliano ^a   Volpe, Massimo ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

ACE inhibitors; Angiotensin type 1 receptor antagonists; End organ damage; Hypertension; Renal function; Renin angiotensin system.

Indexed keywords

AMLODIPINE; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; ANGIOTENSIN RECEPTOR ANTAGONIST; ATENOLOL; CANDESARTAN; CREATININE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; IRBESARTAN; LISINOPRIL; LOSARTAN; OLMESARTAN; PLACEBO; RAMIPRIL; TELMISARTAN; VALSARTAN;

ALBUMINURIA; ANTIHYPERTENSIVE THERAPY; BLOOD PRESSURE REGULATION; CARDIOVASCULAR DISEASE; COMBINATION CHEMOTHERAPY; CREATININE BLOOD LEVEL; DIABETIC NEPHROPATHY; DISEASE COURSE; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG DOSE INCREASE; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG MECHANISM; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; HUMAN; HYPERTENSION; HYPOTENSION; KIDNEY DISEASE; KIDNEY FAILURE; KIDNEY INJURY; MICROALBUMINURIA; MONOTHERAPY; NON INSULIN DEPENDENT DIABETES MELLITUS; OPTIMAL DRUG DOSE; PATHOGENESIS; PATHOPHYSIOLOGY; PROTEINURIA; RANDOMIZED CONTROLLED TRIAL (TOPIC); RENAL PROTECTION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; UNSPECIFIED SIDE EFFECT;

ANGIOTENSIN RECEPTOR ANTAGONISTS; DIABETIC NEPHROPATHIES; HUMANS; HYPERTENSION; KIDNEY DISEASES; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 79958785890     PISSN: 00126667     EISSN: 11791950     Source Type: Journal    
DOI: 10.2165/11591350-000000000-00000     Document Type: Review

References (65)

1. Volpe M, Tocci G, Pagannone E. Angiotensin II-receptor antagonist in the treatment of hypertension. Curr Hypertens Rep 2005 Aug; 7 (4): 287-93. (Pubitemid 41319441)
2. Ruilope LM, Volpe M. Treating hypertension with angiotensin II receptor blockers: a step ahead of blood pressure reduction? High Blood Press Cardiovasc Prev 2005; 12 (1): 9-15. (Pubitemid 41038419)
3. Tocci G, Sciarretta S, Facciolo C, et al. Antihypertensive strategy based on angiotensin II receptor blockers: a new gateway to reduce risk in hypertension. Expert Rev Cardiovasc Ther 2007 Jul; 5 (4): 767-76. (Pubitemid 47053762)
4. Smith DH. Comparison of angiotensin II type 1 receptor antagonists in the treatment of essential hypertension. Drugs 2008; 68 (9): 1207-25. (Pubitemid 351822111)
5. Podar T, Tuomilehto J. The role of angiotensin converting enzyme inhibitors and angiotensin II receptor antagonists in the management of diabetic complications. Drugs 2002; 62 (14): 2007-12. (Pubitemid 35204033)
6. Volpe M, Tocci G, Pagannone E. Fewer mega-trials and more clinically oriented studies in hypertension research? The case of blocking the renin-angiotensin-aldosterone system. J Am Soc Nephrol 2006 Apr; 17 (4 Suppl. 2): S36-43.
7. Volpe M, Tocci G. Therapeutic implications of recent megatrials in hypertension: in favor of new drugs. J Nephrol 2007 Nov-Dec; 20 Suppl. 12: S12-8. (Pubitemid 351266132)
8. Ryden L, Standl E, Bartnik M, et al. Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: executive summary. The Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD). Eur Heart J 2007 Jan; 28 (1): 88-136.
9. Mancia G, De Backer G, Dominiczak A, et al. 2007 ESH-ESC Practice Guidelines for the Management of Arterial Hypertension: ESH-ESC Task Force on the Management of Arterial Hypertension. J Hypertens 2007 Sep; 25 (9): 1751-62. (Pubitemid 47356612)
10. Graham I, Atar D, Borch-Johnsen K, et al. European guidelines on cardiovascular disease prevention in clinical practice: full text. Fourth Joint Task Force of the European Society of Cardiology and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of nine societies and by invited experts). Eur J Cardiovasc Prev Rehabil 2007 Sep; 14 Suppl. 2: S1-113.
11. Kearney PM, WheltonM, Reynolds K, et al. Global burden of hypertension: analysis of worldwide data. Lancet 2005 Jan 15-21; 365 (9455): 217-23. (Pubitemid 40138015)
12. Staessen JA, Wang J, Bianchi G, et al. Essential hypertension. Lancet 2003 May 10; 361 (9369): 1629-41. (Pubitemid 36579003)
13. Lewington S, Clarke R, Qizilbash N, et al. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet 2002 Dec 14; 360 (9349): 1903-13. (Pubitemid 35472129)
14. Turnbull F,Neal B, Algert C, et al. Effects of different blood pressure-lowering regimens onmajor cardiovascular events in individuals with and without diabetes mellitus: results of prospectively designed overviews of randomized trials. Arch Intern Med 2005 Jun 27; 165 (12): 1410-9. (Pubitemid 40973424)
15. Turnbull F, Neal B, Ninomiya T, et al. Effects of different regimens to lower blood pressure on major cardiovascular events in older and younger adults: meta-analysis of randomised trials. BMJ 2008 May 17; 336 (7653): 1121-3. (Pubitemid 351731743)
16. Schmieder RE, Schlaich MP, Klingbeil AU, et al. Update on reversal of left ventricular hypertrophy in essential hypertension (a meta-analysis of all randomized double-blind studies until December 1996). Nephrol Dial Transplant 1998 Mar; 13 (3): 564-9.
17. Strippoli GF, Craig M, Deeks JJ, et al. Effects of angiotensin converting enzyme inhibitors and angiotensin II receptor antagonists on mortality and renal outcomes in diabetic nephropathy: systematic review. BMJ 2004 Oct 9; 329 (7470): 828-39.
18. Boersma E, Keil U, De Bacquer D, et al. Blood pressure is insufficiently controlled in European patients with established coronary heart disease. JHypertens 2003 Oct; 21 (10): 1831-40. (Pubitemid 37290101)
19. Egan BM, Zhao Y, Axon RN. US trends in prevalence, awareness, treatment, and control of hypertension, 1988-.2008. JAMA 2010 May 26; 303 (20): 2043-50.
20. Alderman MH, Ogihara T. Global challenge for overcoming high blood pressure: Fukuoka Statement, 19 October 2006 [letter]. J Hypertens 2007 Mar; 25 (3): 727.
21. Alderman MH, Furberg CD, Kostis JB, et al. Hypertension guidelines: criteria that might make them more clinically useful. Am J Hypertens 2002 Oct; 15 (10 Pt 1): 917-23. (Pubitemid 35168433)
22. Volpe M, Alderman MH, Furberg CD, et al. Beyond hypertension toward guidelines for cardiovascular risk reduction. Am J Hypertens 2004 Nov; 17 (11 Pt 1): 1068-74. (Pubitemid 39469332)
23. Verdecchia P, Schillaci G, Borgioni C, et al. Prognostic significance of serial changes in left ventricular mass in essential hypertension. Circulation 1998 Jan 6-13; 97 (1): 48-54. (Pubitemid 28036154)
24. Volpe M. Microalbuminuria screening in patients with hypertension: recommendations for clinical practice. Int J Clin Pract 2008 Jan; 62 (1): 97-108. (Pubitemid 350294014)
25. Ruggenenti P, Fassi A, Ilieva AP, et al. Preventing microalbuminuria in type 2 diabetes. N Engl J Med 2004 Nov 4; 351 (19): 1941-51. (Pubitemid 39447135)
26. Redon J. Treatment of patients with essential hypertension and microalbuminuria. Drugs 1997 Dec; 54 (6): 857-66. (Pubitemid 27526896)
27. Volpe M, Musumeci B, De Paolis P, et al. Angiotensin II AT2 receptor subtype: an uprising frontier in cardiovascular disease? J Hypertens 2003 Aug; 21 (8): 1429-43. (Pubitemid 36994116)
28. De Paolis P, Porcellini A, Savoia C, et al. Functional crosstalk between angiotensin II and epidermal growth factor receptors in NIH3T3 fibroblasts. J Hypertens 2002 Apr; 20 (4): 693-9. (Pubitemid 34913713)
29. Johnston CI. Biochemistry and pharmacology of the reninangiotensin system. Drugs 1990; 39 Suppl. 1: 21-31.
30. Ribeiro AB, Kohlmann Jr O, Saragoca MA, et al. The reninangiotensin system in the control of systemic arterial pressure. Drugs 1985; 30 Suppl. 1: 6-12. (Pubitemid 15249105)
31. Ferrario CM. Importance of the renin-angiotensin-aldosterone system (RAS) in the physiology and pathology of hypertension: an overview. Drugs 1990; 39 Suppl. 2: 1-8. (Pubitemid 20167008)
32. van Hooft IM, Grobbee DE, Derkx FH, et al. Renal hemodynamics and the renin-angiotensin-aldosterone system in normotensive subjects with hypertensive and normotensive parents. N Engl J Med 1991 May 9; 324 (19): 1305-11.
33. Norris K, Vaughn C. The role of renin-angiotensin-aldosterone system inhibition in chronic kidney disease. Expert Rev Cardiovasc Ther 2003 May; 1 (1): 51-63.
34. The SOLVD Investigators. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. N Engl J Med 1992 Sep 3; 327 (10): 685-91.
35. The SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 1991 Aug 1; 325 (5): 293-302.
36. The CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure: results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N Engl JMed 1987 Jun 4; 316 (23): 1429-35.
37. Swedberg K, Held P, Kjekshus J, et al. Effects of the early administration of enalapril on mortality in patients with acute myocardial infarction: results of the Cooperative New Scandinavian Enalapril Survival Study II (CONSENSUS II). N Engl J Med 1992 Sep 3; 327 (10): 678-84.
38. Biollaz J, Durr J, Brunner HR, et al. Escape from mineralocorticoid excess: the role of angiotensin II. J Clin Endocrinol Metab 1982 Jun; 54 (6): 1187-93. (Pubitemid 13238699)
39. Boehm M, Nabel EG. Angiotensin-converting enzyme 2: a new cardiac regulator. N Engl JMed 2002 Nov 28; 347 (22): 1795-7. (Pubitemid 35375620)
40. Laight DW. Therapeutic inhibition of the renin angiotensin aldosterone system. Expert Opin Ther Pat 2009 Jun; 19 (6): 753-9.
41. Strippoli GF, Bonifati C, Craig M, et al. Angiotensin converting enzyme inhibitors and angiotensin II receptor antagonists for preventing the progression of diabetic kidney disease. Cochrane Database Syst Rev 2006; (4): CD006257.
42. Parving HH, Lehnert H, Brochner-Mortensen J, et al. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 2001 Sep 20; 345 (12): 870-8.
43. Viberti G, Wheeldon NM. Microalbuminuria reduction with valsartan in patients with type 2 diabetes mellitus: a blood pressure-independent effect. Circulation 2002 Aug 6; 106 (6): 672-8. (Pubitemid 34851925)
44. Brenner BM, Cooper ME, de Zeeuw D, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001 Sep 20; 345 (12): 861-9.
45. Lewis EJ, Hunsicker LG, Clarke WR, et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001 Sep 20; 345 (12): 851-60.
46. Bohm M, Thoenes M, Danchin N, et al. Association of cardiovascular risk factors with microalbuminuria in hypertensive individuals: the i-SEARCH global study. J Hypertens 2007 Nov; 25 (11): 2317-24. (Pubitemid 47537927)
47. Sciarretta S, Pontremoli R, Rosei EA, et al. Independent association of ECG abnormalities with microalbuminuria and renal damage in hypertensive patients without overt cardiovascular disease: data from Italy-Developing Education and awareness on MicroAlbuminuria in patients with hypertensive Disease study. J Hypertens 2009 Feb; 27 (2): 410-7.
48. Haller H, Ito S, Izzo Jr JL, et al. Olmesartan for the delay or prevention of microalbuminuria in type 2 diabetes. N Engl J Med 2011 Mar 10; 364 (10): 907-17.
49. Dahlof B, Devereux RB, Kjeldsen SE, et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002 Mar 23; 359 (9311): 995-1003. (Pubitemid 34286536)
50. Hollenberg NK, Parving HH, Viberti G, et al. Albuminuria response to very high-dose valsartan in type 2 diabetes mellitus. J Hypertens 2007 Sep; 25 (9): 1921-6. (Pubitemid 47356634)
51. Ohishi M, Takagi T, Ito N, et al. Renal protective effect in hypertensive patients: the high doses of angiotensin II receptor blocker (HARB) study. Hypertens Res 2007 Dec; 30 (12): 1187-92. (Pubitemid 351176416)
52. Makino H, Haneda M, Babazono T, et al. Prevention of transition from incipient to overt nephropathy with telmisartan in patients with type 2 diabetes. Diabetes Care 2007 Jun; 30 (6): 1577-8. (Pubitemid 46871174)
53. Barnett AH, Bain SC, Bouter P, et al. Angiotensin-receptor blockade versus converting-enzyme inhibition in type 2 diabetes and nephropathy. N Engl J Med 2004 Nov 4; 351 (19): 1952-61. (Pubitemid 39447136)
54. Mogensen CE, Neldam S, Tikkanen I, et al. Randomised controlled trial of dual blockade of renin-angiotensin system in patients with hypertension, microalbuminuria, and non-insulin dependent diabetes: the candesartan and lisinopril microalbuminuria (CALM) study. BMJ 2000 Dec 9; 321 (7274): 1440-4.
55. Menne J, Farsang C, Deak L, et al. Valsartan in combination with lisinopril versus the respective high dose monotherapies in hypertensive patients with microalbuminuria: the VALERIA trial. J Hypertens 2008 Sep; 26 (9): 1860-7.
56. Yusuf S, Teo KK, Pogue J, et al. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med 2008 Apr 10; 358 (15): 1547-59. (Pubitemid 351522739)
57. Imai E, Ito S, Haneda M, et al. Olmesartan reducing incidence of endstage renal disease in diabetic nephropathy trial (ORIENT): rationale and study design.HypertensRes 2006 Sep; 29 (9): 703-9. (Pubitemid 44605369)
58. Lindholm LH, Ibsen H, Dahlof B, et al. Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002 Mar 23; 359 (9311): 1004-10. (Pubitemid 34286537)
59. Kjeldsen SE, Dahlof B, Devereux RB, et al. Effects of losartan on cardiovascular morbidity and mortality in patients with isolated systolic hypertension and left ventricular hypertrophy: a Losartan Intervention For End- point Reduction (LIFE) substudy. JAMA 2002 Sep 25; 288 (12): 1491-8.
60. Os I, Franco V, Kjeldsen SE, et al. Effects of losartan in women with hypertension and left ventricular hypertrophy: results from the Losartan Intervention For Endpoint Reduction in Hypertension Study. Hypertension 2008 Apr; 51 (4): 1103-8. (Pubitemid 351398965)
61. Wachtell K, Hornestam B, Lehto M, et al. Cardiovascular morbidity and mortality in hypertensive patients with a history of atrial fibrillation: the Losartan Intervention For End Point Reduction in Hypertension (LIFE) study. J Am Coll Cardiol 2005 Mar 1; 45 (5): 705-11. (Pubitemid 40282585)
62. Ibsen H, Wachtell K, Olsen MH, et al. Does albuminuria predict cardiovascular outcome on treatment with losartan versus atenolol in hypertension with left ventricular hypertrophy? A LIFE substudy. J Hypertens 2004 Sep; 22 (9): 1805-11. (Pubitemid 39141974)
63. Ibsen H, Olsen MH, Wachtell K, et al. Reduction in albuminuria translates to reduction in cardiovascular events in hypertensive patients: losartan intervention for endpoint reduction in hypertension study. Hypertension 2005 Feb; 45 (2): 198-202. (Pubitemid 40179960)
64. Estacio RO, Coll JR, Tran ZV, et al. Effect of intensive blood pressure control with valsartan on urinary albumin excretion in normotensive patients with type 2 diabetes. Am J Hypertens 2006 Dec; 19 (12): 1241-8. (Pubitemid 44856249)
65. Mann JF, Schmieder RE, McQueen M, et al. Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial. Lancet 2008 Aug 16; 372 (9638): 547-53